News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation's Gilotrif Wins FDA OK for Advanced Lung Cancer


7/12/2013 10:21:07 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The U.S. Food and Drug Administration approved a lung cancer drug made by Boehringer Ingelheim to treat patients who are suffering from late stage non-small cell lung cancer and whose tumors express a specific type of gene mutation. The drug, Gilotrif, was approved along with a companion diagnostic kit that can help determine if a patient's lung cancer cells express the epidermal growth factor receptor (EGFR) gene mutation.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES